Navigation Links
Cardium to Present at Upcoming Investor Conferences
Date:1/4/2012

SAN DIEGO, Jan. 4, 2012 /PRNewswire/ -- Cardium Therapeutics (NYSE Amex: CXM) today announced that it is scheduled to present at the Biotech Showcase 2012 and the 5th Annual OneMedForum Conference in San Francisco.

(Logo: http://photos.prnewswire.com/prnh/20051018/CARDIUMLOGO)

The 2012 Biotech Showcase is being held at the Parc 55 Wyndham in San Francisco and Cardium is scheduled to present on Monday, January 9, 2012 at 4:00 p.m. Pacific.

The 5th Annual OneMedForum Conference is taking place at the Sir Francis Drake Hotel, San Francisco and the Company's presentation is scheduled for Tuesday, January 10, 2012 at 11:00 a.m. Pacific.  OneMedForum Conference provides a live, video web cast that can be found at http://www.onemedplace.com/.

An updated investor presentation is now available on Cardium's website at http://phx.corporate-ir.net/phoenix.zhtml?c=77949&p=irol-presentations.

About Cardium
Cardium is focused on the acquisition and strategic development of new and innovative bio-medical product opportunities and businesses with the potential to address significant unmet medical needs that have definable pathways to commercialization, partnering and other economic monetizations.  Cardium's current medical opportunities portfolio, which is focused on health sciences and regenerative medicine, includes the Tissue Repair Company, Cardium Biologics, and the Company's in-house MedPodium Health Sciences healthy lifestyle product platform.  The Company's lead commercial product Excellagen™ topical gel for wound care management, has recently received FDA clearance for marketing and sale in the United States.  Cardium's lead clinical development product candidate Generx®is a D
'/>"/>

SOURCE Cardium Therapeutics
Copyright©2010 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2

Related biology technology :

1. Cardiums Exchange Listing Compliance Plan Accepted by NYSE Amex
2. Cardium Reports Excellagen Matrix Clinical Study Results Accepted for Publication by Peer-Reviewed Journal, and Updates Product Plans
3. Cardium Reports on Third Quarter 2010 Financial Results and Recent Developments
4. Cardium to Present at the LifeTech Capital Miami Medical Investors Conference
5. Cardium Gains Exclusive Access to Novel Polymer-Based Nitric Oxide Technology for Expansion of Wound Healing Product Portfolio
6. Cardium to Present at 10th Annual Biotech in Europe Investor Forum
7. Cardium Regains Listing Compliance With NYSE Amex
8. Cardium to Present at MDB Capital Groups 2010 Bright Lights Conference
9. Cardiums Exchange Listing Compliance Plan Accepted by NYSE AMEX
10. Cardium Reports on Third Quarter 2009 Financial Results and Recent Developments
11. Cardium Announces Plans to File FDA 510(k) Application for U.S. Marketing Clearance of ExcellagenXL(TM) Gel for Diabetic, Pressure and Venous Ulcers and Other Topical Wounds
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/23/2013)... (PRWEB) May 23, 2013 Can economic ... from work motivate members of the public to increase ... including Johns Hopkins Carey Business School Assistant ... yes. Pointing to a large body of recent research ... the May 24, 2013, issue of Science that the ...
(Date:5/23/2013)... CA (PRWEB) May 23, 2013 The ... encourage all types of inventions. They focus on learning ... noticing this community gravitate toward bringing their ideas to ... DIY Biology Movement, works on making projects using biology. ... DNA of plants to make them glow with bioluminescence ...
(Date:5/23/2013)... Pa. , May 23, 2013 ... research and advisory firms for specialized biopharmaceutical issues, ... hepatologists, and infectious disease specialists reported that in ... patients (e.g., intentionally delaying treatment) in anticipation of ... than six months ago, when only 6 percent ...
(Date:5/23/2013)... , May 23, 2013 Pressure BioSciences, Inc. ... the Company will host a teleconference to discuss its ... business update. The teleconference information is provided below: ... Eastern Daylight Time (EDT) Dial-in: (800) 875-3456 ... 607-2001 (Int,l) Passcode: VS22823 For those unable ...
Breaking Biology Technology:Offering Economic Incentives to Attract Blood Donations Should Be Encouraged, Research Team writes in Science 2Offering Economic Incentives to Attract Blood Donations Should Be Encouraged, Research Team writes in Science 3Glowing Plant Releases Maker Kit, Enabling Anyone to Make a Glowing Plant at Home 2The Majority of Physicians that Treat Hepatitis C Virus (HCV) Have Begun "Warehousing" and Preparing Their HCV Patients for the Next Generation of HCV Treatments 2The Majority of Physicians that Treat Hepatitis C Virus (HCV) Have Begun "Warehousing" and Preparing Their HCV Patients for the Next Generation of HCV Treatments 3Pressure BioSciences, Inc. to Discuss First Quarter 2013 Financial Results and Provide Business Update 2
... 2 Accera, Inc., a biotechnology ... (CNS) diseases, today launched Axona(TM) in the United ... first-in-class medical food for the clinical dietary management ... Dispensed by prescription, it targets the metabolic deficiencies ...
... /PRNewswire-FirstCall/ - Angiotech Pharmaceuticals, Inc. (NASDAQ: ANPI ... new Senior Secured Term Loan and Revolving Credit Facility. ... agent and lender for both the Term Loan and ... draw secured term loan facility of up to $10 ...
... Inc.,(Nasdaq: BNVI ) today announced the online ... Menerba(TM) (formerly MF101) is,well tolerated, safe and effective for ... associated with menopause. , The ... safety and,efficacy of two doses of Menerba versus placebo. ...
Cached Biology Technology:Video: Accera Launches Axona(TM), First Medical Food Therapy to Help Manage Mild-to-Moderate Alzheimer's Disease 2Video: Accera Launches Axona(TM), First Medical Food Therapy to Help Manage Mild-to-Moderate Alzheimer's Disease 3Video: Accera Launches Axona(TM), First Medical Food Therapy to Help Manage Mild-to-Moderate Alzheimer's Disease 4Angiotech Pharmaceuticals, Inc. announces new Senior Secured Term Loan and Credit Facilities 2Angiotech Pharmaceuticals, Inc. announces new Senior Secured Term Loan and Credit Facilities 3Angiotech Pharmaceuticals, Inc. announces new Senior Secured Term Loan and Credit Facilities 4Bionovo Announces Publication of Positive Phase 2 Trial Results for Menerba(TM) 2Bionovo Announces Publication of Positive Phase 2 Trial Results for Menerba(TM) 3Bionovo Announces Publication of Positive Phase 2 Trial Results for Menerba(TM) 4
(Date:5/24/2013)... the immune system to combat metastatic cancer , ... destruction by the immune system. Stimulation of the immune ... are many factors that cause the immune system to ... that function to suppress the immune system response. In ... , researchers led by Ronald Levy at Stanford University ...
(Date:5/24/2013)... microRNAs (miRNAs) and other non-coding RNAs are small ... proteins. In recent years they have emerged as ... establish tissue origin for cancers of unknown primary ... for disease, but clinically tractable, diagnostic methods for ... currently available. In this issue of the ...
(Date:5/24/2013)... medication against Alzheimer,s disease, scientists have focused among other ... (A-beta). After all, it is the accumulation of A-beta that ... Starting point for the formation of A-beta is APP. Alessia ... unravel the function of APPL the fruit-fly version of ... , Alessia Soldano (VIB/KU Leuven): "We have discovered that APPL ...
Breaking Biology News(10 mins):JCI early table of contents for May 24, 2013 2JCI early table of contents for May 24, 2013 3JCI early table of contents for May 24, 2013 4JCI early table of contents for May 24, 2013 5JCI early table of contents for May 24, 2013 6JCI early table of contents for May 24, 2013 7JCI early table of contents for May 24, 2013 8A new strategy required in the search for Alzheimer's drugs? 2
... and scientific experts propose a global framework for the ... including further clinical testing In Australia. The South-Pacific ... anxiety but is restricted in some countries. Leading ... of Melbourne, Australia; Professor Rolf Teschke from Wolfgang Goethe-University, ...
... have made a significant discovery about the nature of ... Tanner, BDS, Ph.D., identified a new pathogen connected to ... wiggsiae , was present in the mouths of children ... such as Streptococcus mutans were not detected. ...
... especially for the excellence of its peacekeepers and ice ... to help countries elsewhere brace for drought, flood and ... year horizon. Within a single generation, recent studies ... by an estimated 40%, with one-third of humanity having ...
Cached Biology News:Experts propose global guidelines for safe use of Kava and new Australian study 2Forsyth team gains new insight on childhood dental disease 2Canada's role grows amid looming world water shortages in some places, more flooding in others 2Canada's role grows amid looming world water shortages in some places, more flooding in others 3Canada's role grows amid looming world water shortages in some places, more flooding in others 4Canada's role grows amid looming world water shortages in some places, more flooding in others 5Canada's role grows amid looming world water shortages in some places, more flooding in others 6Canada's role grows amid looming world water shortages in some places, more flooding in others 7
Lipid Phosphate Phosphohydrolase 2...
Rabbit polyclonal to Phosphothreonine-Proline / Phosphoserine-Proline ( Abpromise for all tested applications)....
ANTI-HUMAN CYTOKINES, GROWTH FACTORS (polyclonal rabbit (or goat) antibodies) Human TARC - Biotin...
Mouse monoclonal [7C6] to Bcr-abl ( Abpromise for all tested applications). SwissProtID: P11274...
Biology Products: